Abstract 163P
Background
Next generation sequencing (NGS) technologies allow for a better understanding of tumors’ biology and the implementation of targeted therapy (TT). We conducted a prospective investigational project at the Catalan Institut of Oncology-Badalona to assess their clinical utility in ABC.
Methods
After obtaining the informed consent of patients (pts) with ABC, Oncomine Comprehensive AssayV3 and the Intrinsic subtype (IS) by Prosigna were applied to analyze genomic profile including mutations (mut) and copy number variants (CNV) of 161 genes. We evaluated clinical and molecular characteristics, TT and the impact of molecular alterations (alt) on treatment decision.
Results
Since November 2021, 64 pts were included, with evaluable genomic results in 54 (29 metastasis and 25 primary tumors). Median age was 59y (37-82). Twenty-three out of 53 (43.4%) pts with hormonal receptor (HR) positive HER2-negative ABC had been treated with >1 line (L) hormone therapy. Thirty-three pts (51.6%) had not received any prior chemotherapy L, 18 (28.1%) 1L, and 13 (20.3%) 2L. The IS distribution was 24 (44.4%) luminal B, 20 (37%) luminal A, 5 HER2-enriched, 5 basal-like (9.3% each), concordant with surrogate subtypes by IHQ in 70.6 %. More than 60 molecular alt were identified in 35 genes (median of 2 alt/patient); 1) mut: 21 (38.8 %) in PI3KCA (84.2% in HR+/HER2- tumors) and 17 (31.5%) in TP53 and 2) CNVs: 14 (25.9%) in FGFR1 and 13 in FGF19 (24%), 12 in CCND1 and ERBB2 (17.7% each). PI3KCA-mut was associated with a lower incidence of other alt compared to non-mut tumors (15 vs 52 additional alt, respectively: Chi-square, p=0.001). Six pts had died at the time of analysis with a median Overall Survival (OS) of 3.4 years. Triple Negative ABC, TP53 and PTEN mut were independently associated with worse progression free survival to 1L and OS (p<0.001). To date, 6 pts (11.1%) have received TT, mainly for PI3KCA mut and up to 25 (39.1%) will be considered for TT at progression.
Conclusions
Based on NGS data, more than 10% of pts benefitted from targeted therapy at the time of analysis, with expected benefit for additional 20%. Noteworthy, NGS adds prognostic information and better selection of sequential therapies. NGS is a key tool for personalised therapies in ABC, requiring more research to optimize its use.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Hospital Germans Trias i Pujol.
Disclosure
M.A. Bergamino: Non-Financial Interests, Personal, Invited Speaker: Eisai; Non-Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Funding: Novartis.M. Romeo Marin: Financial Interests, Personal, Funding: GSK, AstraZeneca, Clovis, MSD. M. Margeli Vila: Financial Interests, Personal, Funding: Novartis, Pfizer, Lilly, Gilead, Pierre Fabre, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract